Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Liang Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7826-3877; OpenAlex author ID A5100648958, A5122290094. Sources: OpenAlex.

Their work

Papers
76 (first author 7, last author 19)
Trials
0
Grants
0
Labs led
2
Collaborators
179
Papers, trials and grants by year

2013: 4 papers · 2014: 8 papers · 2015: 8 papers · 2016: 11 papers · 2017: 5 papers · 2018: 7 papers · 2019: 8 papers · 2020: 5 papers · 2021: 3 papers · 2022: 5 papers · 2023: 2 papers · 2024: 3 papers · 2025: 4 papers · 2026: 3 papers

Papers 50 of 76

  1. Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. Co-author DOI 10.1093/jnci/djag235↗
  2. Gut microbiota and pancreatic cancer: tumorigenesis, progression, and clinical applications. Co-author DOI 10.20892/j.issn.2095-3941.2025.0650↗
  3. [Corrigendum] RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. Last author DOI 10.3892/ijo.2025.5822↗
  4. Tumor-associated macrophages (TAMs): Constructing an immunosuppressive microenvironment bridge for pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1016/j.cpt.2024.07.004↗
  5. Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts. Co-author DOI 10.1016/j.isci.2024.111693↗
  6. Pancreatic surgery is safe in elderly patients with PDAC. Co-author DOI 10.1186/s12877-025-05907-8↗
  7. Development and Validation of a Cell-Free DNA Fragmentomics-Based Model for Early Detection of Pancreatic Cancer. Co-author DOI 10.1200/jco.24.00287↗
  8. Pancreatic STAT5 activation promotes Kras G12D-induced and inflammation-induced acinar-to-ductal metaplasia and pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-332225↗
  9. [A fresh perspective on advances in pancreatic cancer treatment over the past two decades]. Co-author DOI 10.3760/cma.j.cn112139-20240321-00138↗
  10. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Co-author DOI 10.3892/ol.2024.14293↗
  11. Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: Current dilemmas and future directions. Last author DOI 10.1016/j.bbcan.2023.188958↗
  12. Reshaping the Pancreatic Cancer Microenvironment at Different Stages with Chemotherapy. Co-author DOI 10.3390/cancers15092448↗
  13. Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer. Last author DOI 10.1016/j.bbcan.2022.188676↗
  14. A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2022.188751↗
  15. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.01.026↗
  16. Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.104016↗
  17. Identification of characteristic markers correlated with Th2 cell infiltration and metabolism molecular subtype in pancreatic adenocarcinoma. Last author DOI 10.21037/jgo-22-333↗
  18. Bidirectional and dynamic interaction between the microbiota and therapeutic resistance in pancreatic cancer. Last author DOI 10.1016/j.bbcan.2020.188484↗
  19. Neutrophil extracellular DNA traps promote pancreatic cancer cells migration and invasion by activating EGFR/ERK pathway. Last author DOI 10.1111/jcmm.16555↗
  20. Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21. Last author DOI 10.3390/cancers13153678↗
  21. Killing the "BAD": Challenges for immunotherapy in pancreatic cancer. Last author DOI 10.1016/j.bbcan.2020.188384↗
  22. Cancer-associated fibroblasts in therapeutic resistance of pancreatic cancer: Present situation, predicaments, and perspectives. Last author DOI 10.1016/j.bbcan.2020.188444↗
  23. Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective. Last author DOI 10.1016/j.csbj.2020.11.018↗
  24. Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer. Co-author DOI 10.3748/wjg.v26.i8.828↗
  25. Precise and efficient silencing of mutant Kras G12D by CRISPR-CasRx controls pancreatic cancer progression. Co-author DOI 10.7150/thno.46642↗
  26. Angiogenesis in pancreatic cancer: current research status and clinical implications. Last author DOI 10.1007/s10456-018-9645-2↗
  27. Reflections on depletion of tumor stroma in pancreatic cancer. First author DOI 10.1016/j.bbcan.2019.01.007↗
  28. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ejso.2018.10.539↗
  29. Tumor-Infiltrating NETs Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6941-4↗
  30. ASO Author Reflections: Tumor-Infiltrating NETs are New Biomarkers to Predict Postsurgical Survival for Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-019-07169-2↗
  31. Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. Last author DOI 10.2174/0929867325666180413101722↗
  32. The Loss of SMAD4/DPC4 Expression Associated with a Strongly Activated Hedgehog Signaling Pathway Predicts Poor Prognosis in Resected Pancreatic Cancer. Last author DOI 10.7150/jca.30883↗
  33. SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer. Co-author DOI 10.7150/jca.32072↗
  34. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis. First author DOI 10.1016/j.hbpd.2018.03.007↗
  35. Guidelines for the diagnosis and treatment of pancreatic adenocarcinoma (2018 edition): A standardized procedure recommended in China. First author DOI 10.1016/j.hbpd.2018.07.004↗
  36. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.08.003↗
  37. A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-… Co-author DOI 10.1016/j.surg.2018.01.017↗
  38. Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-018-6727-8↗
  39. ASO Author Reflections: Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6737-6↗
  40. The Significance of Liquid Biopsy in Pancreatic Cancer. Last author DOI 10.7150/jca.24591↗
  41. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. Co-author DOI 10.1002/ijc.30650↗
  42. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.surg.2016.08.005↗
  43. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000001741↗
  44. A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. Co-author DOI 10.3892/ijo.2017.3938↗
  45. Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. Co-author DOI 10.3892/ol.2016.5501↗
  46. New insights into perineural invasion of pancreatic cancer: More than pain. Co-author DOI 10.1016/j.bbcan.2016.01.002↗
  47. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.01.054↗
  48. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Co-author DOI 10.1016/j.pan.2016.09.007↗
  49. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Co-author DOI 10.1016/j.pan.2016.09.013↗
  50. Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥ 1,000 U/m… Co-author DOI 10.1038/srep19222↗

Closest collaborators

The 25 strongest of 179 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 60 shared papers, 2013–2026 · strength 4.51
  2. Wenquan Wang · 20 shared papers, 2015–2026 · strength 3.21
  3. Huaxiang Xu · 28 shared papers, 2013–2026 · strength 2.56
  4. Chuntao Wu · 22 shared papers, 2013–2026 · strength 1.68
  5. Jin Xu · 33 shared papers, 2013–2019 · strength 1.64
  6. Quanxing Ni · 26 shared papers, 2013–2019 · strength 1.44
  7. Jiang Long · 29 shared papers, 2013–2020 · strength 1.43
  8. Chen Liu · 29 shared papers, 2013–2018 · strength 1.39
  9. Wen-Quan Wang · 18 shared papers, 2013–2020 · strength 1.38
  10. Shi-Rong Zhang · 9 shared papers, 2018–2026 · strength 0.96
  11. Kaizhou Jin · 14 shared papers, 2015–2022 · strength 0.91
  12. Jin-Zhi Xu · 8 shared papers, 2018–2026 · strength 0.90
  13. He-Li Gao · 8 shared papers, 2018–2026 · strength 0.86
  14. Ning Pu · 4 shared papers, 2023–2026 · strength 0.85
  15. Zi-Hao Qi · 8 shared papers, 2016–2026 · strength 0.80
  16. Guopei Luo · 15 shared papers, 2013–2018 · strength 0.74
  17. Heli Gao · 7 shared papers, 2018–2022 · strength 0.72
  18. Tianjiao Li · 5 shared papers, 2020–2022 · strength 0.63
  19. Shuo Li · 7 shared papers, 2018–2020 · strength 0.61
  20. Meng Guo · 10 shared papers, 2014–2018 · strength 0.54
  21. Jianang Li · 2 shared papers, 2025 · strength 0.54
  22. Runjie Liu · 2 shared papers, 2025 · strength 0.54
  23. Yi Qin · 12 shared papers, 2013–2017 · strength 0.53
  24. Si Shi · 11 shared papers, 2014–2017 · strength 0.50
  25. Zhiwen Xiao · 7 shared papers, 2013–2022 · strength 0.49

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.